Robotic Rehabilitation of the Upper Limb After a Stroke (ROBOASSIST)

February 9, 2023 updated by: Clinique Les Trois Soleils

Rehabilitation Program With Robotic Assistance for the Improvement of Motor Performance and Functional Use of the Upper Limb in Subacute Hemiparetic. Multicenter Randomized Controlled Trial

Hemiparesis is the most common motor disorder after a stroke. Most patients do not recover functional use of their paretic upper limb.

The use of robotic assistance provides intensive motor training through a large number of repetitive movements, usually oriented and interactive tasks (pointing tasks, tracking paths tasks...). These feature have been demonstrated to be critical to stimulate brain plasticity after a brain damage. The InMotion Arm 2.0 manipulator works with an adaptive algorithm that provide patients with real-time Assistance-as-Needed™ desgned to enhance motor performance.

Hypothesis: In the sub-acute phase of stroke, the structured practice of a large number of repeated movements will increase motor function of the upper limb compared to conventional rehabilitation. Secondly, this practice will be more effective in a free active mode (without assistance) than an active assisted mode (Assistance-as-Needed™).

Expected secondary benefits: Subjective impression of improved use of the upper limb in activities of daily living and reduction of spastic cocontractions affecting the agonist and antagonist muscles during movements of the upper limb.

Objectives: This randomized controlled trial will evaluate the effects of structured repetition programs of arm movements, on the function of the hemiparetic upper limb and motor control, between 4 and 10 weeks after the stroke, using a robotic device with or without assistance in partial substitution of conventional rehabilitation care, compared to a program with conventional care alone.

Study Overview

Status

Terminated

Conditions

Study Type

Interventional

Enrollment (Actual)

54

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Boissise-le-Roi, France, 77310
        • Clinique Les Trois Soleils
      • Créteil, France, 94010
        • Hôpitaux Universitaires Henri Mondor

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 100 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age ≥18 years;
  • Stroke hemiparesis on unilateral focal lesion dating from 4 to 10 weeks at baseline;
  • Active flexion of the paretic shoulder ≥15 °;
  • Average score on the modified scale of Frenchay <5;
  • Patient having agreed to sign an informed consent.

Exclusion Criteria:

  • Passive extension of the paretic elbow <120 °;
  • Passive extension of the paretic wrist <10 °;
  • Cognitive dysfunction or progressive intercurrent illness making effective communication or participation in the study impossible;
  • Infection, inflammation or complex regional pain syndrome of the paretic upper extremity;
  • Injection of botulinum toxin to the upper limb less than 3 months old;
  • Patient under safeguard of justice;
  • Patient include in an other clinical trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Conventional rehabilitation
5 sessions / week of 1 hour of occupational therapy
Conventional rehabilitation implemented by an occupational therapist, involving stretching movements in submaximal passive amplitude, inhibition postures (Bobath), active efforts assisted of varied difficulty, exercises of direction of the arm towards a target with or without elbow support and grasping tasks, adapted to the capacities of the paretic upper limb.
ACTIVE_COMPARATOR: Robotic rehabilitation with assistance
5 sessions / week of 1 hour of rehabilitation of the upper limb with 30 min of conventional rehabilitation and 30 min of robotic rehabilitation with assistance.
Conventional rehabilitation implemented by an occupational therapist, involving stretching movements in submaximal passive amplitude, inhibition postures (Bobath), active efforts assisted of varied difficulty, exercises of direction of the arm towards a target with or without elbow support and grasping tasks, adapted to the capacities of the paretic upper limb.
Repetitive work of large numbers of targeted alternative movements with or without assistance. The passage between with and without assistance taking place according to the evolution of performance judged by the investigator therapist. Note that the duration of the training using the assisted mode should be at least 3 weeks, i.e. half of the total duration of treatment.
ACTIVE_COMPARATOR: Non-assistance robotic rehabilitation
5 sessions / week of 1 hour of rehabilitation of the upper limb including 30 min of conventional rehabilitation and 30 min of robotic rehabilitation without assistance.
Conventional rehabilitation implemented by an occupational therapist, involving stretching movements in submaximal passive amplitude, inhibition postures (Bobath), active efforts assisted of varied difficulty, exercises of direction of the arm towards a target with or without elbow support and grasping tasks, adapted to the capacities of the paretic upper limb.
Repetitive work of large numbers of targeted alternative movements with or without assistance. The passage between with and without assistance taking place according to the evolution of performance judged by the investigator therapist. Note that the duration of the training using the assisted mode should be at least 3 weeks, i.e. half of the total duration of treatment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional performance score change on Modified Frenchay Scale
Time Frame: Between the pre-rehabilitation state on the day of program start (Day1) and the state at the end of the program (Week6)
The scale measures active upper limb function in hemiparesis based on 10 everyday living tasks, each rated on a 10-point visual analogic scale. Six tasks are bimanual and four are unimanual performed with the paretic hand. Final score is an average of the 10 subscores (10 is the higher score).
Between the pre-rehabilitation state on the day of program start (Day1) and the state at the end of the program (Week6)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional performance score change on Modified Frenchay Scale
Time Frame: between Day1 (day of program start) and Week22 (16 weeks after the end of the program)
The scale measures active upper limb function in hemiparesis based on 10 everyday living tasks, each rated on a 10-point visual analogic scale. Six tasks are bimanual and four are unimanual performed with the paretic hand. Final score is an average of the 10 subscores (10 is the higher score).
between Day1 (day of program start) and Week22 (16 weeks after the end of the program)
Change of motor performance score on the Fugl-Meyer score
Time Frame: between Day1(day of program start), Week6(end of the program) and Week22 (16 weeks after the end of the program)
Fugl-Meyer (FM) assessment for measures of the motor impairment of the upper-limb; the test includes items related to movements of the shoulder, elbow, forearm (proximal arm), and wrist and hand (distal arm). The total scores range between 0 and 66.
between Day1(day of program start), Week6(end of the program) and Week22 (16 weeks after the end of the program)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in perceived function score on the Disability Assessment Scale (DAS)
Time Frame: between Day1(day of program start), Week6(end of the program) and Week22 (16 weeks after the end of the program)
The scale evaluates upper limb functional disability in patients with spasticity following stroke. Patients are interviewed to determine the extent of functional impairment for the following 4 areas: hygiene,dressing, limb position, pain.The DAS Scale uses a 4-point rating scale according to the following criteria: 0(no disability),1 (mild disability), 2 (moderate disability) and 3(severe disability).
between Day1(day of program start), Week6(end of the program) and Week22 (16 weeks after the end of the program)
Change in perceived function score on the Global Subjective Self Assessment (GSSA)
Time Frame: between Day1(day of program start), Week6(end of the program) and Week22 (16 weeks after the end of the program)
Three questions were asked to the patient, relating to pain, stiffness-induced discomfort and active function. Each rating was registered by the patient using a visual analogue scale ranging from 0 (worst pain imaginable, worst discomfort imaginable, arm totally useless, respectively) to 10 (no pain, no stiffness-induced discomfort, normal function, respectively).
between Day1(day of program start), Week6(end of the program) and Week22 (16 weeks after the end of the program)
Angle and grade of spasticity of the shoulder extensors, flexors and elbow pronators, clinically measured by the Tardieu modified scale
Time Frame: at Day1(day of program start), Week6(end of the program) and Week22 (16 weeks after the end of the program)
The scale is a clinical measure of muscle spasticity for use with patients with neurological conditions. Spasticity is quantified by assessing the muscle's response to stretch applied at given velocities.
at Day1(day of program start), Week6(end of the program) and Week22 (16 weeks after the end of the program)
Paresis angle of shoulder flexion, extension and supination of the elbow;
Time Frame: at Day1(day of program start), Week6(end of the program) and Week22 (16 weeks after the end of the program)
Paresis angle of shoulder flexion (maximal passive amplitude - maximal active amplitude)
at Day1(day of program start), Week6(end of the program) and Week22 (16 weeks after the end of the program)
Kinematic data of the movements based on the robot's records
Time Frame: at Day1(day of program start), Week6(end of the program) and Week22 (16 weeks after the end of the program)
at Day1(day of program start), Week6(end of the program) and Week22 (16 weeks after the end of the program)
Maximum motor force measured by the robot of the abductor/adductor and flexors/extensors of the shoulder
Time Frame: at Day1(day of program start), Week6(end of the program) and Week22 (16 weeks after the end of the program)
at Day1(day of program start), Week6(end of the program) and Week22 (16 weeks after the end of the program)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 30, 2014

Primary Completion (ACTUAL)

April 22, 2015

Study Completion (ACTUAL)

July 11, 2022

Study Registration Dates

First Submitted

June 19, 2018

First Submitted That Met QC Criteria

July 11, 2018

First Posted (ACTUAL)

July 12, 2018

Study Record Updates

Last Update Posted (ACTUAL)

February 13, 2023

Last Update Submitted That Met QC Criteria

February 9, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Conventional rehabilitation

3
Subscribe